Chinese delegation visits Israel to research cannabis Print

With the recent governmental announcement that Israel will be facilitating more active investment into cannabis medical research and exports, a delegation of Chinese businessmen and academic researchers in the fields of technology and agriculture arrived in Israel last month to meet with Israeli cannabis researchers.

Israel is considered a leader when it comes to medical cannabis-related research, with both the Government and academia having participated actively in this field for decades. Raphael Mechoulam, a professor of medicinal chemistry at the Hebrew University of Jerusalem, was the first person to identify the main psychoactive constituent in cannabis, THC.

The country’s relatively advanced regulatory framework when it comes to medical trials with cannabinoids facilitates research: over 70 startups developing cannabis-related technology and products currently operate in Israel, most of them established in recent years. Last month Tel Aviv-based cannabis inhaler company Syqe Medical Ltd. raised a US$50 million funding round.

As part of the visit, the delegation aimed to seek scientific collaborations. Ascher Shmulewitz, chairman of Israeli cannabis company Therapix Biosciences Ltd., accompanied the delegation during the visit.

(Issue Feb 2019)